CD157 is also expressed in >85% of malignant pleural mesothelioma, where high CD157 levels are associated in vitro with enhanced tumorigenic potential and with reduced sensitivity to platinum-based chemotherapy, especially in the biphasic histotype [45]. This evidence concerns the gene BST1 and malignant pleural mesothelioma.